Search company, investor...

Intas Pharmaceuticals

Founded Year



Secondary Market - IV | Alive

Total Raised




About Intas Pharmaceuticals

Intas Pharmaceuticals is a provider of pharmaceutical services. It specializes in pharmaceutical formulation development, manufacturing, and marketing. The firm serves clients in the healthcare sector. It was founded in 1977 and is based in Ahmedabad, India.

Headquarters Location

Corporate House, Near Sola Bridge S. G. Highway, Thaltej

Ahmedabad, 380054,


+91 79 6652 3100

Missing: Intas Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Intas Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Intas Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Intas Pharmaceuticals is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,899 items

Intas Pharmaceuticals Patents

Intas Pharmaceuticals has filed 1 patent.

The 3 most popular patent topics include:

  • Antineoplastic drugs
  • Experimental cancer drugs
  • Monoclonal antibodies
patents chart

Application Date

Grant Date


Related Topics




Piperazines, Dosage forms, Drug delivery devices, Atypical antipsychotics, Fluoroarenes


Application Date


Grant Date



Related Topics

Piperazines, Dosage forms, Drug delivery devices, Atypical antipsychotics, Fluoroarenes



Latest Intas Pharmaceuticals News

Intas Pharmaceuticals Ltd. marches into the Guinness World Records

Nov 21, 2022

The jute and ply sheets used to create the record will be donated to NGOs to enable supportive action for the unprivileged members of society.With an aim to trigger a change and move the world towards better prostate health, Intas one of the leaders in Urology Therapy in India, conceptualised and launched an Awareness Ribbon Initiative with the active support of more than 10,000 doctors from all across India, making a positive impact on the lives of more than 1 million patients. PTI | Ahmedabad | Updated: 21-11-2022 11:23 IST | Created: 21-11-2022 11:19 IST Image Credit: PRNewswire SHARE Intas Pharmaceuticals Ltd., one of the leading pharmaceutical multinationals, has successfully set a Guinness World Record by creating the World's 'Largest Awareness Ribbon made by Awareness Ribbons' with the help of more than 10,000 healthcare professionals. This historic feat was achieved at Hyatt Regency, Ahmedabad , during the 32nd World Video Urology Conference [17th to 19th Nov 22], under the supervision of an official from Guinness World Records, London , who handed over the certificate for the record to Intas on 19th November 2022. Every element utilized for the creation of this award is eco-friendly and reusable. This includes the material of the ribbons and the jute base for placing the same. Intas plans to later distribute these ribbons among Doctors across the nation to continue driving the prostate care awareness momentum across the nation. The jute and ply sheets used to create the record will be donated to NGOs to enable supportive action for the unprivileged members of society. With an aim to trigger a change and move the world towards better prostate health, Intas one of the leaders in Urology Therapy in India , conceptualised and launched an Awareness Ribbon Initiative with the active support of more than 10,000 doctors from all across India , making a positive impact on the lives of more than 1 million patients. This World Record is an extension of that initiative and an effort to attract global attention towards this noble cause. Globally, the month of November is celebrated as ''Movember'', to create more awareness regarding prostate health and other issues related to men. Prostate health and other health disorders in men are often taken as age-related diseases. Most of it can be managed with the right clinical intervention. However, millions of men continue to suffer due to a lack of awareness. Elaborating the ideology behind the initiative, a spokesperson from Intas shared that ''More than the honor, we hope this initiative achieves its objective of creating increased awareness about prostate health in men. We need many more such initiatives that can guide our society toward a healthier and happier future. At Intas , we have always strived to make a positive difference in the lives of our patients with advanced and accessible medication. With such initiatives, we just keep broadening the realms of care for our society and nation.'' About Intas Pharmaceuticals Limited Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad , India , having end-to-end capabilities of formulation development, manufacturing and marketing along with backward integration of APIs. The organization has more than 18,000 employees and 14 manufacturing sites worldwide and sells products in more than 85 countries. The Intas Group's revenue amounted to USD 2.5 bn in FY 2021-22 and the compounded annual growth rate of revenue has been 22% in the past 5 years. For more information, please visit Photo - Photo - (This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.) READ MORE ON:

Intas Pharmaceuticals Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Intas Pharmaceuticals Rank

Intas Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Intas Pharmaceuticals founded?

    Intas Pharmaceuticals was founded in 1977.

  • Where is Intas Pharmaceuticals's headquarters?

    Intas Pharmaceuticals's headquarters is located at Corporate House, Near Sola Bridge, Ahmedabad.

  • What is Intas Pharmaceuticals's latest funding round?

    Intas Pharmaceuticals's latest funding round is Secondary Market - IV.

  • How much did Intas Pharmaceuticals raise?

    Intas Pharmaceuticals raised a total of $57M.

  • Who are the investors of Intas Pharmaceuticals?

    Investors of Intas Pharmaceuticals include Platinum Owl, Capital International Private Equity Funds, ChrysCapital, Temasek and ICICI Venture.

  • Who are Intas Pharmaceuticals's competitors?

    Competitors of Intas Pharmaceuticals include Unither Pharmaceuticals, Acura Pharmaceuticals, Itaconix, KBI Biopharma, Nanomed Pharmaceuticals and 13 more.

Compare Intas Pharmaceuticals to Competitors


Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

Appian International Research

Appian aims to provide consulting and operational support in pharmaceutical product development. The company grew out of the contract pharmaceutical research industry. Dr. Grier Harris, Appian's President, has worked in clinical trials since 1986 in most areas within the industry - from basic medical research to large scale international clinical trials.

Inflabloc Pharmaceuticals

Inflabloc Pharmaceuticals, Inc. is engaged in the research and development of pharmaceutical treatments for inflammatory disorders. Inflabloc's current product development is based on its discoveries of strong anti-inflammatory properties of dehydroepiandrosterone (DHEA), a steroid that is produced in the adrenal gland. The company's lead product line is a DHEA combination treatment. The company has 4 products in development. IP-1001 is slated to enter Phase 2 clinical trials in Crohn's disease later this year. IP-1002 has completed Phase 1. IP-1003 recently established proof-of-concept in an inflammatory bowel disease (IBD) animal model, while IP-1005 has just entered proof-of-concept testing in a C-reactive protein (CRP) mouse model.

Morria Biopharmaceuticals

Morria's lead products are first-in-class synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAID). These drugs target a known but previously elusive key event in the inflammation process upstream of current competitors while simultaneously protecting cells and tissues against inflammatory damage and stimuli. Morria has two lead products (MRX4 for allergic rhinitis and MRX6 for contact dermatitis) scheduled for clinical trials in late 2007 and a growing library of additional compounds. Double blind placebo controlled human pilot-studies for contact dermatitis have been successfully completed in Israel .nMorria is also currently engaged in research agreements with three global pharmaceutical leaders in the fields of ophthalmology, eye-care and cardiovascular medicine.

Onepharm Research and Development

Onepharm Research and Development offers a product isolated from a medicinal plant, with anti-inflammatory activity

Marksans Pharma

Marksans Pharma (formerly Glenmark Laboratories) is one of the pharmaceuticals company in India, with a focused approach on creating a world class, global, pharmaceutical company. Its manufacturing plant is an in Asia and is approved by UK-MCHRA and Australian-TGA authorities. Marksans' focus is to become a preferred supplier for formulation outsourcing by first world countries, develop a marketing presence in the EU and, through a combination of licensing and partnering, become a integrated pharmaceutical company. It has just completed the reverse takeover of TASC Pharmaceuticals, a publicly quoted API company, to form a corporation valued at $120 million.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.